Welcome

Welcome to the fourth issue of the ROADMAP newsletter!

This fourth newsletter provides you with up to date information on the project's latest progress. 2017 has been a very busy year, ROADMAP celebrated its first birthday and we are glad to announce that our consortium has officially grown to 26 partners, including the University of Bordeaux (Memento), Takeda, Lundbeck and the University of Leiden as our partners. The consortium is making great progress and ROADMAP partners presented and discussed the project at various events with international key decision makers.

Enjoy!

Frédéric De Reydet De Vulpillieres

Project Leader (on behalf of EFPIA) and WorldWide Market Access Director NS at Novartis

Scientific involvement

Real-world evidence, a learning opportunity

Prof. Johan van der Lei

Head of the Department of Medical Informatics, WP4 Co-leader

Today’s post is an interview with Prof. Johan van der Lei (Head of the Department of Medical Informatics) at Erasmus University. He will introduce us to real-world evidence as a learning opportunity and tell us about the roots of his work that led to the current research Work Package 4 is conducting, as well as how the Disease Modelling and Simulation team - which is co-led by him and Billy Amzal - contributes to a potential ROADMAP phase 2.

Pick of the season

2nd ROADMAP consultation with the European Working Group of People with Dementia

On 7 December, Alzheimer Europe and ROADMAP colleagues from the University of Oxford organised a consultation with the European Working Group of People with Dementia (EWGPWD). This consultation contributes to the Ethical, Legal and Social Implications (ELSI) work package of ROADMAP and set out to explore concerns that may be raised by sharing, re-using and combining health data to create a real-world evidence platform for AD research.

ROADMAP progress update

The ROADMAP team has been busy since the last newsletter, and here we give you a brief overview and update of what has been happening across the work packages.

Review of past regulatory and health technology assessments of Alzheimer’s disease medicines

In this article Marieke Dekker (Scientific Researcher at the Medicines Evaluation Board, CBG-MEB) gives us a quick insight into a current evaluation of past experiences of regulatory and HTA bodies with AD approved drugs and the second phase of this project.

Recently submitted deliverables

We are happy to announce the submission of three deliverables to the IMI

D2.2.1 Report of systematic review of published and unpublished data identifying important and relevant outcomes in AD and criteria for disease progression
A group of systematic literature reviews is under way to collate all available evidence on which outcomes of Alzheimer’s disease (AD) are most important, and what constitutes a meaningful delay in its progression, from the perspectives of people with AD, their carers and healthcare professionals.

D2.3.1 Stakeholder generated lists of priority real world evidence relevant outcomes for Alzheimer’s disease
A series of stakeholder activities is in process to define a priority set of real world dementia focussed outcomes across the disease spectrum and to define what constitutes a meaningful delay in disease progression.

D6.1 Interim report on the EXAG activities and outputs
This report outlines the background and membership of the Expert Advisory Group (EXAG) , which has been established under Work Package 6, to ensure the relevance and usability of ROADMAP activities and outputs to regulators and HTA agencies throughout the project.

Meet the ROADMAP team update

Since the last newsletter the ROADMAP team has been extremely busy bringing ROADMAP to the public, dementia community and scientific attention. This part of the newsletter features articles about presentations and events where ROADMAP has been presented and discussed to and with various audiences.

ROADMAP at Alzheimer Europe Conference AEC27

This first article revolves around the ROADMAP introduction held on 4 October at the Alzheimer Europe Conference in Berlin, entitled "Engaging with patient organisations within IMI consortia" as part of a special Lilly Symposium, presented by Catherine Reed.

You can find a the video here in our new video section of the website

You can find the symposium leaflet with further information here

ROADMAP holds 4th General Assembly in Barcelona

On 16 and 17 October, the partners of the ROADMAP project met for the 4th General Assembly Meeting in Barcelona, Spain.

On 18 October, Barcelona (Spain), WP6 – which focuses on regulatory and Health Technology Assessment (HTA) engagement – organised the first Regulatory, HTA, and payer Expert Advisory Group (EXAG) meeting for the ROADMAP project.

On 16-18 October, the European Prevention of Alzheimer’s dementia (EPAD) project organised its first IMI-AD Platform Disease Modelling Workshop in Edinburgh, UK.

On 5 and 6 December 2017, Alzheimer Europe (AE) hosted its third annual Alzheimer’s Association Academy in Brussels, Belgium.

Stay up-to-date on ROADMAP events

Copyright © 2017 ROADMAP, All rights reserved.

Our mailing address is:
info@roadmap-alzheimer.org
Sign up for our list!
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This email was sent to <<Email Address>>
why did I get this? unsubscribe from this list update subscription preferences
ROADMAP · Alzheimer Europe · 14 rue Dicks · Luxembourg L-1417 · Luxembourg